10 completed, 5 terminated, 4 withdrawn, 3 recruiting. 26 Phase 2, 5 Phase 1, 3 Phase 3.
Follow Short Bowel Syndrome: new trials by email Literature Review of Short Bowel Syndrome trials Research Report on Short Bowel Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). TRA16, Placebo - Enteric Hyperoxaluria | Phase 2 | Not yet recruiting | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | 30 | 2027-03-01 | 2026-10-13 |
| A Clinical Study of FT1 in Patients With Short Bowel Syndrome FT1, Placebo - Short Bowel Syndrome, SBS | Phase 2 | Recruiting | Chongqing Peg-Bio Biopharm Co., Ltd. | 8 | 2026-08-30 | 2026-07-15 |
| Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) Crofelemer Powder for Oral Solution, Matched Placebo Powder for Oral Solution - Short Bowel Syndrome, Malabsorption Syndromes | Phase 2 | Recruiting | Napo Therapeutics, S.p.A. | 18 | 2025-05-29 | 2026-06-09 |
| Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects HM15912 Active, Placebo - Short Bowel Syndrome | Phase 2 | Recruiting | Hanmi Pharmaceutical Company Limited | 18 | 2022-03-03 | 2026-08-12 |
| Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure Sucrase, Placebo - Short Gut Syndrome | Phase 2 | Terminated | University of Miami | 3 | 2022-01-31 | 2025-10-01 |
| Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC) Apraglutide - Short Bowel Syndrome | Phase 2 | Completed | VectivBio AG | 10 | 2021-06-14 | 2025-06-18 |
| VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome. Vurolenatide 50mg/PBO, Vurolenatide 100mg/PBO, Vurolenatide 50/50 mg - Short Bowel Syndrome | Phase 2 | Terminated | 9 Meters Biopharma, Inc. | 12 | 2021-06-14 | 2022-12-20 |
| Use of Tocofersolan (VedropĀ®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children Tocofersolan - Short Bowel Syndrome, Vitamin E Deficiency | Phase 2 | Withdrawn | Boston Children's Hospital | 2020-12-01 | 2020-05-13 | |
| Proof of Concept Study in Patients With Short Bowel Syndrome NM-002 - Short Bowel Syndrome | Phase 1 / Phase 2 | Unknown | 9 Meters Biopharma, Inc. | 12 | 2020-06-23 | 2020-11-20 |
| Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome Enteric-Coated Cholestyramine (ECC) Capsule, Placebo - Short Bowel Syndrome | Phase 2 | Terminated | Pharmascience Inc. | 13 | 2019-10-15 | 2022-07-19 |
| Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support FE203799 GLP-2 analogue, FE203799 Placebo GLP-2 analogue - Short Bowel Syndrome | Phase 1 / Phase 2 | Completed | GlyPharma Therapeutics | 8 | 2018-05-08 | 2024-10-26 |
| Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency FE203799 - SBS - Short Bowel Syndrome | Phase 1 / Phase 2 | Completed | GlyPharma Therapeutics | 8 | 2018-05-02 | 2024-10-24 |
| Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) Liraglutide Pen Injector [Victoza] - Short Bowel Syndrome | Phase 2 | Withdrawn | Imperial College London | 2017-10-20 | 2020-08-14 | |
| Use of Pancreatic Enzymes in Short Bowel Syndrome Pancreatic Enzyme - Short Bowel Syndrome | Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2017-03-24 | 2020-03-20 |
| Safety and Efficacy Study in Infant With SBS NTRA-9620, Placebo - Short Bowel Syndrome | Phase 2 / Phase 3 | Terminated | Elgan Pharma Ltd. | 2 | 2017-03-20 | 2021-10-12 |
| A Phase 2 Trial Testing ZP1848 in Patients With SBS ZP1848 - Short Bowel Syndrome | Phase 2 | Completed | Zealand Pharma | 18 | 2016-02-01 | 2017-06-21 |
| Compassionate Use of Omegaven in Children Omegaven - Total Parenteral Nutrition-induced Cholestasis, Cholestasis | Phase 2 / Phase 3 | Completed | University of Oklahoma | 63 | 2015-06-01 | 2019-11-25 |
| Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies Microlipid with fish oil, Microlipid - Prematurity, Intestine Perforation | Phase 2 | Completed | Wake Forest University | 18 | 2012-10-01 | 2018-12-04 |
| Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure Glucagon-Like Peptide 2, Glucagon like peptide-2 - Intestinal Failure, Short Bowel Syndrome | Phase 1 / Phase 2 | Terminated | Alberta Children's Hospital | 13 | 2012-01-01 | 2014-12-23 |
| Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome 70% ethanol - Catheter Related Infections, Short Bowel Syndrome | Phase 2 | Withdrawn | Boston Children's Hospital | 2011-02-01 | 2017-06-22 |
Showing 20 of 26. Sign in to see all of them.
Cholestasis (4) · Intestinal Failure (4) · Enterocolitis, Necrotizing (2) · Gastrointestinal Diseases (2) · Gastroschisis (2) · Intestinal Atresia (2) · Catheter-Related Infections (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Hyperphagia (1) · Infant Nutrition Disorders (1) · Infant, Premature, Diseases (1) · Intestinal Perforation (1) · Kidney Calculi (1)
Digestive System Diseases (26) · Intestinal Diseases (26) · Pathologic Processes (26) · Pathological Conditions, Signs and Symptoms (26) · Malabsorption Syndromes (25) · Postoperative Complications (25) · Gastrointestinal Diseases (24) · Bile Duct Diseases (4) · Biliary Tract Diseases (4) · Gastroenteritis (3) · Nutritional and Metabolic Diseases (3) · Pathological Conditions, Anatomical (3) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Abnormalities (2)
fish oil triglycerides (3) · Fish Oils (2) · Capsules (1) · Corn Oil (1) · Diet Therapy (1) · Ethanol (1) · Glucagon-Like Peptide 2 (1) · Growth Hormone (1) · Liraglutide (1) · Omacor (1) · Pancrelipase (1) · Safflower Oil (1) · Solutions (1) · Sucrase (1) · apraglutide (1)
Boston Children's Hospital (3) · 9 Meters Biopharma, Inc. (2) · GlyPharma Therapeutics (2) · Alberta Children's Hospital (1) · Amarnath, Rathna, M.D. (1) · Children's Hospital of Philadelphia (1) · Chongqing Peg-Bio Biopharm Co., Ltd. (1) · Elgan Pharma Ltd. (1) · Emory University (1) · Hanmi Pharmaceutical Company Limited (1) · Imperial College London (1) · Mark Puder (1) · Napo Therapeutics, S.p.A. (1) · Pharmascience Inc. (1) · The Hospital for Sick Children (1)
United States (14) · Denmark (4) · Belgium (2) · Canada (2) · France (2) · Germany (2) · Poland (2) · United Kingdom (2) · China (1) · Italy (1) · South Korea (1)
Tomasz Masior (3) · Amanda Fifi, MD (1) · Christopher Duggan, M.D, MPH (1) · David Sigalet, MD PhD (1) · Gertrud Koefoed Rasmussen, MSc (1) · Kimberly D Ernst, MD, MSMI (1) · Kinga Szczepanek, MD (1) · Konrad Matysiak, MD, PhD (1) · Marek Kunecki, MD, PhD (1) · Natalie Terry, MD, PhD (1) · Paul Wales (1) · Qing Yang, MD, PhD (1) · Ricardo A. Caicedo, MD (1) · Siddhartha Oke (1) · Terra R Varner, PharmD (1)
PMID 19661785, PMID 20980771, PMID 21324480, PMID 23453547, PMID 26838529, PMID 30880176, PMID 31326433, PMID 32059815, PMID 33038344, PMID 34287970, PMID 34287979, PMID 34695449, PMID 35622082, PMID 39461299, PMID 41903849
2018 (1), R01DK055850 (1)